CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...
After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback